Mikki Royston
Family · Broussard, LANPI 1184356511
Payments from drug & device makers
Across 100 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$376
- Exact Sciences$148
- AstraZeneca$118
- Novo Nordisk$107
- Lilly USA, LLC$102
- Pfizer$96
- plus $671 from 16 others
What the payments were for
- Food & beverage$1,618100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $376 |
| Exact Sciences | 8 | $148 |
| AstraZeneca | 7 | $118 |
| Novo Nordisk | 6 | $107 |
| Lilly USA, LLC | 6 | $102 |
| Pfizer | 5 | $96 |
| Axsome Therapeutics, Inc. | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $83 |
| GSK | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Corium, LLC | 6 | $66 |
| Ardelyx, Inc. | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $40 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| Amgen | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Biogen | 1 | $19 |
| Exeltis, USA Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Silk Road Medical, Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $16 |
How this compares
$1,618 in reported general payments places this provider in the 70th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 22 | $25,700 |
| MounjaroTirzepatide | 12 | $20,726 |
| LinzessLinaclotide | 16 | $8,443 |
| EliquisApixaban | 13 | $7,329 |
| JardianceEmpagliflozin | 12 | $7,046 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,480 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $422 |
| Atorvastatin Calcium | 44 | $294 |
| Escitalopram Oxalate | 15 | $232 |
| Pioglitazone Hcl | 13 | $179 |
| Metformin Hcl | 11 | $137 |
| Valsartan | 15 | $132 |
| Diclofenac Sodium | 18 | $129 |
| Amlodipine Besylate | 12 | $128 |
| Trazodone Hcl | 14 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $107 | $25,70022 claims |
| Lilly USA, LLCMounjaro | $102 | $20,72612 claims |
| AbbVieLinzess | $376 | $8,44316 claims |
| PfizerEliquis | $96 | $7,32913 claims |
| Boehringer IngelheimJardiance | $17 | $7,04612 claims |
| AstraZenecaSymbicort | $118 | $2,48011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,610 family providers in Louisiana.
Other family in Broussard
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.